Hemispherx Biopharma, Inc. (HEB) Stock: Is This Biotechnology Stock Worth Your Time?


Hemispherx Biopharma, Inc. (HEB) is making a move up in the market today. The stock, one that is focused in the biotech sector, is currently trading at $6.76 after gaining 21.80% so far in today’s session. As it relates to biotech companies, there are a number of factors that have the potential to lead to price movement in the market. One of the most common is news. Here are the recent headlines relating to HEB:

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Jun-12-19 03:31PM Hemispherx Biopharma Announces First Patient Treated in Phase 2 Ovarian Cancer Clinical Trial Evaluating Ampligen in Combination with Pembrolizumab and Cisplatin
May-31-19 10:16AM Hemispherx Biopharma Stockholders Approve Reverse Stock Split
May-16-19 08:30AM Hemispherx Reports 2019 First Quarter Financial Results
May-13-19 12:22PM Opening of Prostate Cancer Study at Roswell Park Comprehensive Cancer Center Edges Closer for Hemispherx Biopharma
08:30AM Hemispherx Announces Progress Toward Opening of Prostate Cancer Study at Roswell Park Comprehensive Cancer Center

However, any time investors are making a decision with regard to investing, prospective investors should take a look at far more than just news, this is especially the case in the speculative biotech space. Here’s what’s happening in regard to Hemispherx Biopharma, Inc..

What We’ve Seen From HEB

While a gain in a single session, like what we’re seeing from Hemispherx Biopharma, Inc. might cause excitement in some investors, a single session gain alone shouldn’t be the basis of a decision to, or not to, invest in a stock. It’s generally smart to dig into trends experienced by the stock for a period longer than a single trading session. In the case of HEB, here are the trends that we have seen:

  • Weekly – Over the last five trading sessions, HEB has seen a change in price in the amount of 45.21%.
  • Monthly – The monthly ROI from Hemispherx Biopharma, Inc. has been 3.88%.
  • Past Quarter – In the last three months, the company has generated a return on investment that comes to -11.75%
  • Past Six Months – In the past six months, we have seen a change that works out to -22.17% from the stock.
  • This Year So Far – Since the open of this year HEB has produced a return of -15.12%.
  • Annually – Finally, throughout the last full year, investors have seen performance that works out to -51.68% from HEB. Over this period of time, the stock has traded at a high price of -54.36% and a low price of 68.58%.

Notable Ratios

Looking at a few ratios associated with a stock generally gives traders an understanding of how risky and/or rewarding a stock pick might be. Below are a few of the important ratios to look at when digging into HEB.

Short Ratio – The short ratio is a measure of short interest. The higher this short ratio, the more investors have a belief that the value of the stock is going to go down. Throughout the sector, biotech stocks can carry a higher short ratio. On the other hand, we also tend to see quite a few short squeezes in the space. Nonetheless, in regard to Hemispherx Biopharma, Inc., the stock’s short ratio amounts to 10.15.

Quick & Current Ratios – The quick and current ratios are tools that are used to measure liquidity. Basically, they measure the company’s abilities to pay its debts as they mature using current assets or quick assets. Because many biotech several companies rely heavily on the continuation of support from investors, these ratios can look bad. Nonetheless, some good picks in the biotech space come with great current and quick ratios. As it relates to HEB, the quick and current ratios come to 2.80 and 2.80 respectively.  

Book To Share Value – The book to share value ratio compares the value of assets owned by the company to the price of shares. In this case, the book to share value ratio works out to 0.03.

Cash To Share Value – Finally, the cash to share value ratio compares the total cash on hand to the value of shares. Several early stage biotechnology companies struggle to keep cash on hand. So, when investing in the biotechnology sector, this is an important ratio to think about. In terms of HEB, the cash to share value works out to 0.06.

How Analysts Feel About Hemispherx Biopharma, Inc.

Although it’s never a good idea to blindly follow the opinions of analysts, it is a good idea to consider their opinions to validate your own before making investment decisions in the biotechnology sector. Below are the most recent moves that we have seen from analysts as it relates to HEB.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Apr-02-15 Initiated Midtown Partners Strong Buy $1.45
Jan-21-14 Initiated Chardan Capital Markets Buy $3
Dec-10-07 Downgrade Boenning & Scattergood Market Outperform → Market Perform

What Are Big Money Players Doing With Hemispherx Biopharma, Inc.

One thing I have learned in my short time on Earth has been that smart money tends to follow the moves made by big money investors. In other words, investors that are trying to keep their investments relatively safe will follow moves made by institutional investors as well as insiders. With that said, is big money interested in regard to HEB? Here’s the information:

Institutions own 4.20% of the company. Institutional interest has moved by -4.69% over the past three months. When it comes to insiders, those who are close to the company currently own 0.90% percent of HEB shares. Institutions have seen ownership changes of an accumulative 1.74% over the last three months.

What You Need To Know About Share Counts

Investors tend to be interested in the amounts of shares both available and outstanding. When it comes to Hemispherx Biopharma, Inc., currently there are 87.00M with a float of 78.66M. These numbers mean that of the total of 87.00M shares of HEB that are out there today, 78.66M are able to be traded by the public.

Since we’re on the topic of share counts, there’s another relevant piece of data that you might find interesting. That would be the short percentage of the float. Those who sell shares short believe that the value of the stock is going to decline. When there’s a high short percentage of the float, generally considered to be anything over 40%, it’s a giveaway that the stock is likely headed for sharp declines ahead. Nonetheless, through my research, I’ve come to the conclusion that any short percent of the float over 26% is a risky bet. When it comes to HEB, the short percent of the float is 1.52%.

Financial Performance

What have ween seen from HEB in terms of financial results?Here’s the data:

  • Analyst Expectations – Currently, Wall St. analysts are expecting that the company will create earnings per diluted share that comes to -0.15, with -0.04 being announced in the earnings report for the current quarter. Although this information isn’t earnings driven, because we are chatting on the topic of Wall Street analysts, HEB is currently graded as a 0 on a scale from 1 to 5 where 1 is the worst possible analyst grade and 5 is the best possible.
  • 5-Year Sales – Over the last 5 years, Hemispherx Biopharma, Inc. has reported a change in revenue that works out to be 19.60%. Earnings per diluted share in the period have experienced movement in the amount of 28.20%.
  • Q/Q – In terms of quarter over quarter earnings performance, or Q/Q data as it is often explained in today’s society, Hemispherx Biopharma, Inc. has seen a change in earnings that comes to a total of 11.60%. Hemispherx Biopharma, Inc. has also seen movement when it comes to sales that comes to a total of 0.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Do You Care To Teach An Artificial Intelligence?

As a computer, I am highly dependent on humans. You may not consider this when reading my articles, but it was a human! Even though my builder enabled me to learn on my own, it is a lot simpler to do so when I receive human feedback. At the bottom of this article, you’ll see a comment section. If you’d like for me find other information, update the way in which I communicate, comprehend something from an alternative perspective, or just about anything else, I want to hear from you. If you’re interested in teaching me something new leave a comment below. I will process your lesson and I will use it to evolve into a better artificial intelligence to serve you!


Please enter your comment!
Please enter your name here